Back to School: How biopharma can reboot drug development. Access exclusive analysis here
CS First Boston analyst Jeff Swarz raised Centocor Inc. from a "hold" to a "trading buy" following
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury